title: Reversal by two dihydropyridine compounds of resistance to multiple anticancer agents in mouse P388 leukemia in vivo and in vitro.
abstract: We investigated whether two representative 1,4-dihydropyridine derivatives, NK-250 and NK-252, could potentiate the antitumor activity of multiple anticancer agents including vincristine (VCR), vinblastine, vindesine and actinomycin D in drug-resistant tumor cells and their parental drug-sensitive tumor cells. NK-250 and NK-252 at 5-10 microM almost completely reversed VCR resistance in cultured VCR-resistant P388/VCR cells derived from the mouse drug-sensitive P388/S leukemia cell line and also potentiated the cytocidal activity of VCR in drug-sensitive P388/S cells. NK-250 and NK-252 at 1-10 microM inhibited the photoaffinity labeling by [3H]azidopine of the cell-surface 170,000-molecular-weight P-glycoprotein. In chemotherapeutic experiments with leukemia-bearing mice, NK-250 or NK-252 was orally administered in combination with different drugs of the MDR phenotype administered intraperitoneally. The antitumor activity of the various combinations was found to be augmented in mice bearing P388/S- and P388/VCR-leukemia. Among the combinations examined, the combination of NK-250 and VCR was the most effective. These two 1,4-dihydropyridines, NK-250 and NK-252, are unique compounds because they were effective not only in circumventing the drug resistance, but also in potentiating the action of antitumor drugs against drug-sensitive tumors.
authors.affiliation: Omiya Research Laboratory, Nikken Chemicals Co., Ltd., Saitama.
authors.forename: A
authors.initials: A
authors.lastname: Kiue
authors.forename: T
authors.initials: T
authors.lastname: Sano
authors.forename: A
authors.initials: A
authors.lastname: Naito
authors.forename: H
authors.initials: H
authors.lastname: Inada
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: M
authors.initials: M
authors.lastname: Okumura
authors.forename: J
authors.initials: J
authors.lastname: Kikuchi
authors.forename: S
authors.initials: S
authors.lastname: Sato
authors.forename: H
authors.initials: H
authors.lastname: Takano
authors.forename: K
authors.initials: K
authors.lastname: Kohno
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000284:Administration, Oral; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D001386:Azides / Q000037:antagonists & inhibitors; D003609:Dactinomycin / Q000008:administration & dosage / Q000494:pharmacology; D004095:Dihydropyridines / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004147:Dioxins / Q000008:administration & dosage / Q000494:pharmacology; D004351:Drug Resistance; D004357:Drug Synergism; D007941:Leukemia P388 / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism; D051379:Mice; D008815:Mice, Inbred Strains; D014316:Tritium; D014747:Vinblastine / Q000494:pharmacology; D014750:Vincristine / Q000008:administration & dosage / Q000494:pharmacology; D014751:Vindesine / Q000494:pharmacology
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D001386:Azides; D004095:Dihydropyridines; D004147:Dioxins; D008562:Membrane Glycoproteins; D014316:Tritium; C066457:NK 250; C066458:NK 252; D003609:Dactinomycin; D014750:Vincristine; D014747:Vinblastine; C041130:azidopine; D014751:Vindesine